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Abstract: Occurrence of chronic subdural hematoma (CSDH) in leukemia is rare, and 
most reported cases occurred in relation with acute myeloid leukaemia; however, 
occurrence is extremely rare in accelerated phase of chronic myelogenous leukaemia 
(CML). Seizure as presentation of SDH development in CML cases is   not reported in 
literature. Authors report an elderly male, who was diagnosed as CML, accelerated phase 
of developing SDH.  Initially  presented to local physician with seizure; urgent  CT  scan 
head was advised, but ignored and sensorium rapidly worsened over next day and   
reported to our emergency department in  deeply comatose  state, where  imaging 
revealed chronic subdural hematoma with hypoxic brain injury with fatal outcome.   
Seizure, progressive worsening of headache, vomiting and papilloedema are harbinger 
of intracranial space occupying lesion and requires   CT head in emergency medical 
department for exclusion, who are receiving treatment of haematological malignancy. 
Key words: chronic myeloid leukaemia, accelerated phase, chronic subdural hematoma, 
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Introduction 
SDH is an important cause of morbidity 
and mortality and its common aetiology 
includes trauma, medications i.e. 
anticoagulants, antiplatelets, chemotherapy; 
arterio-venous malformation, aneurysms and 
post-craniotomy.  It is very rarely associated 
with haematological malignancy, mostly 
known to occurring with acute myeloid 
leukaemia; however occurrence in chronic 
myelogenous leukaemia (CML) is unusual and 
about less than ten are reported to developing 
in accelerated phase. (1, 2, 3, 7, 10) 
Management of SDH requires appropriate 
computed tomography (CT) scan of head to 
detect amount of hematoma, mass effect, and 
suitability of surgical intervention and 
presence of co-morbid illness. Temporary 
measures may include administration of 
antiepileptic and cerebral decongestants. 
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Cornerstone of management is burr-hole 
drainage of SDH, rarely craniotomy is 
indicated if membranes are well organized and 
thick.  
Case report   
 61 year old gentle man reported to   
emergency services in altered sensorium with 
history of respiratory distress for   past two 
days. He had   no previous history of trauma. 
Although    diagnosed as chronic remission 
phase of CML for eight years, unfortunately he 
developed accelerated phase   since three 
months and kept on chemotherapy.  Co-
morbid illness   included history of acute 
coronary ischemia two months back.  He 
developed   headache and one episode of 
generalised tonic-clonic seizure unassociated 
with aura or postictal weakness. Evaluated by 
local physician at first encounter, CT scan 
head was advised but not done due to non-
availability of CT scan facility at native place. 
He notice progressive worsening of headache 
and lapsed into comma next day   and he was 
brought to   emergency services in altered 
sensorium and respiratory distress. 
Examination in emergency department 
revealed pulse rate was 64 per minute and B.P. 
was 140/ 94 mm Hg, with G.C.S. of 4, with 
dilated and non-reacting left pupil and 
sluggishly reacting right pupil, fundi showed 
with bilateral papilloedema. He was 
immediately intubated and kept on ventilator 
support. Haematological evaluation showed 
anaemia with total leukocyte count (TLC) of 
34100 and marked neutrophilia, peripheral 
blood smear showed anisocytosis with 
dimorphic R.B.C. Bone marrow aspiration and 
biopsy findings were consistent with 
accelerated phase of CML. 
Urgent CT scan head showed presence of 
large chronic subdural hematoma over left 
fronto-temporo-parietal region with 
significant compressed ipsilateral lateral 
ventricle, sub-falcine herniation, midline shift 
of about 9 mm towards right side, trans-
tentorial herniation along with evolving 
ischemic-hypoxic injury of brain (Figure 1). 
Urgent left frontal and parietal burr hole and 
SDH evacuation and drain placement was 
carried out. Post-operative CT head showed 
evidence of global ischemia (Figure 2). He 
succumbed within 24 hours of admission 
despite optimal efforts.   
 
Figure 1 - NCCT head showing large chronic 
subdural hematoma over left fronto-temporo-parietal 
 region causing   sub-falcine herniation and gross 
midline shift 
 
 
Figure 2 - Post-operative NCCT head scan showing 
diffuse hypoxic brain injury 
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Discussion   
 CML is characterized by increased 
proliferation of the granulocytic cell line 
without   loss of capacity to differentiate. Its 
course is clinically sub-classified into three 
phases – chronic phase, accelerated   and blast 
crisis. About 85 % CML patients remain in 
chronic phase, carrying favorable prognosis 
with maintenance chemotherapeutic agents, 
but can convert to other phases with 
unfavorable prognosis when untreated or 
chemotherapeutic resistant cases. 
Predominant factor in differentiating between 
accelerated and blast crisis is percentage of 
myeloblasts present in blood or bone marrow 
study. (6, 14) 
Although tyrosine kinase inhibitors   have 
revolutionized CML therapy with 80-90 % 
long- term survival rates (8). Few such cases on 
long- term chemotherapy   can develop 
chronic SDH despite normal haematological 
parameters, and surgical treatment may be 
required if causing clinically symptomatic or 
producing mass effect. (7, 9)  SDH is rarely 
reported in systemic haematological 
malignancies. (1, 2, 3, 7, 10, 11, 13)  Exact 
mechanisms of SDH development is not clear, 
however, possible mechanism include 
malignant cells deposition   in duramater 
leading to dural blood vessels occlusion and 
causing rupture of occluded vessels into 
subdural space producing CSDH. (11) Other 
postulates are tumour necrosis in metastatic 
deposits, thrombocytopenia, development of 
disseminated intravascular coagulation, and 
secondary adverse effect of chemotherapy 
administration. (7, 9) Druker et al, observed 
that incidence of intracranial haemorrhage in 
CML on medication is about 5 % in blast crisis, 
1 % in accelerated phase and sharply falling to 
0.6 % in chronic phase. (4) 
Our case was in accelerated phase on 
chemotherapy.  Seizure may be presenting 
symptom of intrinsic brain pathology or extra-
axial intracranial lesion. Authors reported 
seizure can be the first presenting symptom in 
extra-axial lesions like pituitary adenoma. (12) 
Hauser et al reported causes of first onset 
seizure in relation to age, idiopathic category 
accounted for more than 50 % of cases but, only 
45 % of cases in the oldest age group. (5) 
Amongst children, the greatest proportion were 
associated with neurological deficits, believed to 
be present since birth, among young age 
population (15-40 years) with an identified 
etiology included central nervous system (CNS) 
infection, tumor, neurological deficit since 
birth and birth trauma were identified  as a 
cause with equal frequency. In adult age (35-64 
years) with presumed causes trauma and 
neoplasms were equally responsible, but less 
frequent with cerebrovascular disease. However 
in the elderly population, most common cause 
was cerebrovascular disease which account for 
28 % of all new cases. So seizure is important 
warning signs of harbouring intracranial 
pathology especially in young or elderly age, 
which require full investigation and accordingly 
appropriate treatment, patient should be 
referred to neurologist or neurosurgeon. 
However in our case unfortunate delay in CT 
scan led to delay in detection of SDH, which 
was only picked up in the advanced stage and 
although urgent surgical intervention could not 
provide good outcome. Hence authors 
recommend every case of seizure and associated 
symptoms of raised intracranial pressure need 
full clinical evaluation including appropriate 
neuro-imaging. 
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Conclusion 
This case report highlights the importance 
of urgent diagnosis and appropriate 
neurosurgical intervention in cases of 
underlying systemic haematological 
malignancies with high index of suspicion for 
raised ICP owing to suspected intracranial 
bleed. Seizure, progressive headache, vomiting 
and papilledema on fundus examination are 
warning signs of harbouring intracranial mass 
lesion, and every case should undergo at least 
CT head, which is economic, easily available 
and requires very short time to rule out life 
threatening intracranial pathology. Proper 
awareness among physician in medical 
emergency department is of paramount 
importance to avoid such delay and providing 
lifesaving therapeutic intervention at the 
earliest opportunity. 
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